Literature DB >> 1689701

Characterization of monoclonal antibodies against the Escherichia coli hemolysin.

S Pellett1, D F Boehm, I S Snyder, G Rowe, R A Welch.   

Abstract

Twelve monoclonal antibodies (MAbs) produced against the Escherichia coli hemolysin (HlyA) encoded by the hemolysin recombinant plasmid pWAM04 were studied. HlyA derivatives from recombinant strains with different plasmids encoding HlyA amino-terminal and carboxy-terminal truncates, HlyA in-frame deletions, and HlyA frameshift mutations were used in immunoblots to localize the antigenic determinants for the anti-HlyA MAbs. The mapping of the MAb epitopes was also facilitated by immunoblotting analysis of HlyA polypeptide fragments derived by cyanogen bromide cleavage. The HlyA epitopes for 11 of the MAbs were mapped to relatively small linear regions of the cytolysin ranging from 28 to 160 amino acids. Five of the MAbs (C10, G8, E2, B7, and D12) neutralized HlyA hemolytic activity to varying degrees. The epitopes for these neutralizing MAbs were found to reside within the following HlyA regions: C10 and G8, amino acids 2 to 160; E2, amino acids 161 to 194; B7, amino acids 518 to 598; and D12, amino acids 626 to 726. Hemolytically active HlyA was dependent on the action of the hlyC gene product. The D12 MAb recognized only HlyA produced by strains with an intact hlyC function. MAb A10 recognized an epitope within the HlyA region from amino acids 728 to 829 where a glycine-rich repeat domain exists; however, this MAb did not neutralize HlyA hemolytic activity. A HlyA domain map showing the anti-HlyA epitope location was constructed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689701      PMCID: PMC258539          DOI: 10.1128/iai.58.3.822-827.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Isolation of fragments of ribosomal proteins that recognize rRNA.

Authors:  L M Changchien; R Conrad; G R Craven
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

2.  Purification and kinetic studies of the hemolysin from Escherichia coli.

Authors:  P Zwadyk; I S Snyder
Journal:  Can J Microbiol       Date:  1971-06       Impact factor: 2.419

3.  Alkaline phosphatase which lacks its own signal sequence becomes enzymatically active when fused to N-terminal sequences of Escherichia coli haemolysin (HlyA).

Authors:  K Erb; M Vogel; W Wagner; W Goebel
Journal:  Mol Gen Genet       Date:  1987-06

4.  The repeat domain of Escherichia coli haemolysin (HlyA) is responsible for its Ca2+-dependent binding to erythrocytes.

Authors:  A Ludwig; T Jarchau; R Benz; W Goebel
Journal:  Mol Gen Genet       Date:  1988-11

5.  Nucleotide sequence of the leukotoxin genes of Pasteurella haemolytica A1.

Authors:  R Y Lo; C A Strathdee; P E Shewen
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

6.  Escherichia coli hemolysin is released extracellularly without cleavage of a signal peptide.

Authors:  T Felmlee; S Pellett; E Y Lee; R A Welch
Journal:  J Bacteriol       Date:  1985-07       Impact factor: 3.490

7.  DNA sequence of the Pasteurella haemolytica leukotoxin gene cluster.

Authors:  S K Highlander; M Chidambaram; M J Engler; G M Weinstock
Journal:  DNA       Date:  1989 Jan-Feb

8.  Alterations of amino acid repeats in the Escherichia coli hemolysin affect cytolytic activity and secretion.

Authors:  T Felmlee; R A Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Release of a chimeric protein into the medium from Escherichia coli using the C-terminal secretion signal of haemolysin.

Authors:  N Mackman; K Baker; L Gray; R Haigh; J M Nicaud; I B Holland
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

10.  Isolation and analysis of the C-terminal signal directing export of Escherichia coli hemolysin protein across both bacterial membranes.

Authors:  V Koronakis; E Koronakis; C Hughes
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  26 in total

1.  Mutations affecting pore formation by haemolysin from Escherichia coli.

Authors:  A Ludwig; A Schmid; R Benz; W Goebel
Journal:  Mol Gen Genet       Date:  1991-04

2.  Characterization of monoclonal antibodies against alpha-hemolysin of Escherichia coli.

Authors:  R L Oropeza-Wekerle; P Kern; D Sun; S Muller; J P Briand; W Goebel
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 3.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

4.  The Actinobacillus pleuropneumoniae hemolysin determinant: unlinked appCA and appBD loci flanked by pseudogenes.

Authors:  Y F Chang; R Young; D K Struck
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

5.  Identification of RTX toxin target cell specificity domains by use of hybrid genes.

Authors:  C Forestier; R A Welch
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

6.  Domains of Escherichia coli hemolysin (HlyA) involved in binding of calcium and erythrocyte membranes.

Authors:  D F Boehm; R A Welch; I S Snyder
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  Prelytic and lytic conformations of erythrocyte-associated Escherichia coli hemolysin.

Authors:  M Moayeri; R A Welch
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.

Authors:  T G Gleason; C W Houlgrave; A K May; T D Crabtree; R G Sawyer; W Denham; J G Norman; T L Pruett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Cytotoxic activity of the Proteus hemolysin HpmA.

Authors:  K G Swihart; R A Welch
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

10.  The HpmA hemolysin is more common than HlyA among Proteus isolates.

Authors:  K G Swihart; R A Welch
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.